Citations (82)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Janakiraman Subramanian & Ossama Tawfik. (2021) Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective. Expert Review of Anticancer Therapy 21:8, pages 877-886.
Read now
Read now
Lei Huang, Kun Xie, Hongwen Li, Ruiqin Wang, Xiaoqing Xu, Kaiming Chen, Hua Gu & Jianmin Fang. (2020) Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody. Drug Design, Development and Therapy 14, pages 3201-3214.
Read now
Read now
Johan Filip Vansteenkiste, Charlotte Van De Kerkhove, Els Wauters & Pierre Van Mol. (2019) Capmatinib for the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy 19:8, pages 659-671.
Read now
Read now
Alessandro Granito, Elena Guidetti & Laura Gramantieri. (2015) c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma. Journal of Hepatocellular Carcinoma 2, pages 29-38.
Read now
Read now
Dongheon Lee, Eun-Sil Sung, Jin-Hyung Ahn, Sungwon An, Jiwon Huh & Weon-Kyoo You. (2015) Development of antibody-based c-Met inhibitors for targeted cancer therapy. ImmunoTargets and Therapy 4, pages 35-44.
Read now
Read now
Camillo Porta, Palma Giglione, Alessandra Ferrari, Francesca Reversi, Wanda Liguigli, Ilaria Imarisio & Carlo Ganini. (2015) Tivantinib (ARQ197) in hepatocellular carcinoma. Expert Review of Anticancer Therapy 15:6, pages 615-622.
Read now
Read now
Qiang Zhen, Jun-Feng Liu, Jia-Bao Liu, Ren-Feng Wang, Wei-Wei Chu, Ya-Xiao Zhang, Guo-Liang Tan, Xiao-Jian Zhao & Bao-Lei Lv. (2015) Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells. Cancer Biology & Therapy 16:4, pages 549-557.
Read now
Read now
Articles from other publishers (75)
Mandy Sakamoto & Tejas Patil. (2023) MET alterations in advanced non-small cell lung cancer. Lung Cancer 178, pages 254-268.
Crossref
Crossref
Elena Michaels & Christine M. Bestvina. (2022) Meeting an un-MET need: Targeting MET in non-small cell lung cancer. Frontiers in Oncology 12.
Crossref
Crossref
Han Yao, Yuanyuan Ren, Jun Yan, Jiadai Liu, Jinhui Hu, Ming Yan & Xingshu Li. (2022) Design, Synthesis, and Evaluation of New Mesenchymal–Epithelial Transition Factor (c-Met) Kinase Inhibitors with Dual Chiral Centers. Molecules 27:17, pages 5359.
Crossref
Crossref
Amandeep Thakur, Chetna Faujdar, Ram Sharma, Sachin Sharma, Basant Malik, Kunal Nepali & Jing Ping Liou. (2022) Glioblastoma: Current Status, Emerging Targets, and Recent Advances. Journal of Medicinal Chemistry 65:13, pages 8596-8685.
Crossref
Crossref
Nisha S Ramani, Ajaykumar C Morani & Shengle Zhang. (2022)
MET
Gene High Copy Number (Amplification/Polysomy) Identified in Melanoma for Potential Targeted Therapy
. American Journal of Clinical Pathology 157:4, pages 502-505.
Crossref
Crossref
Niamh Coleman, Alice Harbery, Sara Heuss, Igor Vivanco & Sanjay Popat. (2022) Targeting un-MET needs in advanced non-small cell lung cancer. Lung Cancer 164, pages 56-68.
Crossref
Crossref
Anqi Wang, Wen Yang, Yue Li, Yang Zhang, Jieqi Zhou, Ruochen Zhang, Weijie Zhang, Jianjie Zhu, Yuanyuan Zeng, Zeyi Liu & Jian-an Huang. (2022) CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway. Cell Communication and Signaling 20:1.
Crossref
Crossref
Leylah M. Drusbosky, Richa Dawar, Estelamari Rodriguez & Chukwuemeka V. Ikpeazu. (2021) Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Mark A. Socinski, Nathan A. Pennell & Kurtis D. Davies. (2021)
MET
Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations
. JCO Precision Oncology:5, pages 653-663.
Crossref
Crossref
Qiang Lu, Yunfeng Ni, Wuping Wang, Lei Wang, Tao Jiang & Lei Shang. (2021) Dynamin 3 Inhibits the Proliferation of Non-small-Cell Lung Cancer Cells by Suppressing c-MET–GBR2–STAT3 Complex Formation. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Hao-Xin Gui, Jun Peng, Ze-Ping Yang, Lu-Yao Chen, Hong Zeng, Yu-Ting Shao, Xi Mu, Qian Hao, Yang Yang, Su An, Xiao-Xi Guo, Tian-Rui Xu & Ying Liu. (2021) HDAC1–Smad3–mSin3A complex is required for Smad3-induced transcriptional inhibition of hepatocyte growth factor receptor in human lung cancers. Carcinogenesis 42:4, pages 587-600.
Crossref
Crossref
Yi-Long Wu, Egbert F. Smit & Todd M. Bauer. (2021) Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies. Cancer Treatment Reviews 95, pages 102173.
Crossref
Crossref
Yangbing Jin, Zehui Zhang, Siyi Zou, Fanlu Li, Hao Chen, Chenghong Peng, Xiaxing Deng, Chenlei Wen, Baiyong Shen & Qian Zhan. (2021) A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Meet Patel, Adam Eckburg, Shahina Gantiwala, Zachary Hart, Joshua Dein, Katie Lam & Neelu Puri. (2021) Resistance to Molecularly Targeted Therapies in Melanoma. Cancers 13:5, pages 1115.
Crossref
Crossref
Hironori Tsujimoto, Minako Kobayashi, Hidekazu Sugasawa, Satoshi Ono, Yoji Kishi & Hideki Ueno. (2021) Potential mechanisms of tumor progression associated with postoperative infectious complications. Cancer and Metastasis Reviews 40:1, pages 285-296.
Crossref
Crossref
Kinan El Husseini, Nouha Chaabane, Audrey Mansuet-Lupo, Karen Leroy, Marie-Pierre Revel & Marie Wislez. (2020) Capmatinib-induced interstitial lung disease: A case report. Current Problems in Cancer: Case Reports 2, pages 100024.
Crossref
Crossref
Ulrike Glaenzel, Yi Jin, Regine Hansen, Kirsten Schroer, Gholamreza Rahmanzadeh, Ulrike Pfaar, Jan Jaap van Lier, Hubert Borell, Axel Meissner, Gian Camenisch & Sylvia Zhao. (2020) Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite. Drug Metabolism and Disposition 48:10, pages 873-885.
Crossref
Crossref
Yubo Wang, Panwen Tian, Lei Xia, Li Li, Rui Han, Mengxiao Zhu, Analyn Lizaso, Tian Qin, Min Li, Bing Yu, Xinru Mao, Han Han-Zhang & Yong He. (2020) The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy. Lung Cancer 146, pages 165-173.
Crossref
Crossref
Qian Qian, Changping Wu, Jianping Chen & Weibing Wang. (2020) Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines. BioMed Research International 2020, pages 1-14.
Crossref
Crossref
Hironori Tsujimoto, Hiroyuki Horiguchi, Yusuke Matsumoto, Risa Takahata, Nariyoshi Shinomiya, Takao Yamori, Hiromi Miyazaki, Satoshi Ono, Daizoh Saitoh, Yoji Kishi & Hideki Ueno. (2020) A Potential Mechanism of Tumor Progression during Systemic Infections Via the Hepatocyte Growth Factor (HGF)/c-Met Signaling Pathway. Journal of Clinical Medicine 9:7, pages 2074.
Crossref
Crossref
Kshipra S. Karnik, Ishudeep Singh Narula, Aniket P. Sarkate & Pravin S. Wakte. (2020) Auto QSAR‐ A Fast Approach for Creation and Application of QSAR Models through Automation. ChemistrySelect 5:19, pages 5756-5762.
Crossref
Crossref
Paerhati Shayimu, Jing‐Bin Wang, Lin Liu, Rousidan Tuerdi, Cun‐Guo Yu & Aikeremu Yusufu. (2019) miR‐922 regulates apoptosis, migration, and invasion by targeting SOCS1 in gastric cancer. The Kaohsiung Journal of Medical Sciences 36:3, pages 178-185.
Crossref
Crossref
Dmitry S. Mikhaylenko, Alexey V. Klimov, Vsevolod B. Matveev, Svetlana I. Samoylova, Vladimir V. Strelnikov, Dmitry V. Zaletaev, Ludmila N. Lubchenko, Boris Y. Alekseev & Marina V. Nemtsova. (2020) Case of Hereditary Papillary Renal Cell Carcinoma Type I in a Patient With a Germline MET Mutation in Russia. Frontiers in Oncology 9.
Crossref
Crossref
Sapana Sameer Chaudhary, Sameer Choudhary, Sakshi Rawat, Gouri Ahir, Anwar L. Bilgrami & Ghulam Md Ashraf. 2020. Cancer-Leading Proteases. Cancer-Leading Proteases
295
326
.
Yutaka Yonemura, Haruaki Ishibashi, Akiyoshi Mizumoto, Kazuo Nishihara, Yang Liu, Satoshi Wakama, Syouzou Sako, Nobuyuki Takao, Masumi Ichinose, Shun-ichi Motoi, Keizou Taniguchi, Sachio Fushida, Yoshio Endou & Masahiro Miura. 2020. Pathology of Peritoneal Metastases. Pathology of Peritoneal Metastases
1
26
.
Weihua Hou, Qingyun Yuan, Xingxing Yuan, Yuxiong Wang, Wei Mo, Huijie Wang & Min Yu. (2018) A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer. Investigational New Drugs 37:5, pages 876-889.
Crossref
Crossref
Vishnu C. Damalanka, Scott A. Wildman & James W. Janetka. (2019) Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin. MedChemComm 10:9, pages 1646-1655.
Crossref
Crossref
Yi Gu, Yang Sai, Jian Wang, Meijing Yu, Guanglin Wang, Li Zhang, Hongcan Ren, Shiming Fan, Yongxin Ren, Weiguo Qing & Weiguo Su. (2019) Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor. European Journal of Pharmaceutical Sciences 136, pages 104938.
Crossref
Crossref
Michaela Poliaková, Andrea Felser, Katarzyna Pierzchala, Jean‐Marc Nuoffer, Daniel Matthias Aebersold, Yitzhak Zimmer, Nicola Zamboni & Michaela Medová. (2019)
Metabolomics reveals tepotinib‐related mitochondrial dysfunction in
MET
‐activating mutations‐driven models
. The FEBS Journal.
Crossref
Crossref
Ratnakar Singh, Shaohua Peng, Pavitra Viswanath, Vaishnavi Sambandam, Li Shen, Xiayu Rao, Bingliang Fang, Jing Wang & Faye M Johnson. (2019)
Non‐canonical
cM
et regulation by vimentin mediates Plk1 inhibitor–induced apoptosis
. EMBO Molecular Medicine 11:5.
Crossref
Crossref
David S. Hong, Patricia LoRusso, Omid Hamid, Filip Janku, Muaiad Kittaneh, Daniel V.T. Catenacci, Emily Chan, Tanios Bekaii-Saab, Shirish M. Gadgeel, Robert D. Loberg, Benny M. Amore, Yuying C. Hwang, Rui Tang, Gataree Ngarmchamnanrith & Eunice L. Kwak. (2019) Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research 25:8, pages 2403-2413.
Crossref
Crossref
Arunachalam Muthuraman, Seema Mehdi & Narahari Rishitha. 2019. Nanoparticles in Pharmacotherapy. Nanoparticles in Pharmacotherapy
73
112
.
Chiara Modica, Dora Tortarolo, Paolo Comoglio, Cristina Basilico & Elisa Vigna. (2018) MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk. International Journal of Molecular Sciences 19:12, pages 3920.
Crossref
Crossref
Manoj Kumar Kashyap & Omar Abdel-Rahman. (2018) Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma. Molecular Cancer 17:1.
Crossref
Crossref
Elaine Vickers. 2018. A Beginner's Guide to Targeted Cancer Treatments. A Beginner's Guide to Targeted Cancer Treatments
65
109
.
Elaine Vickers. 2018. A Beginner's Guide to Targeted Cancer Treatments. A Beginner's Guide to Targeted Cancer Treatments
33
63
.
Mahdia Benkhoucha, Nicolas Molnarfi, Gürkan Kaya, Elodie Belnoue, Kristbjörg Bjarnadóttir, Pierre‐Yves Dietrich, Paul R Walker, Denis Martinvalet, Madiha Derouazi & Patrice H Lalive. (2017)
Identification of a novel population of highly cytotoxic c‐Met‐expressing CD8
+
T lymphocytes
. EMBO reports 18:9, pages 1545-1558.
Crossref
Crossref
Pamela J. Farrell, Jennifer Matuszkiewicz, Deepika Balakrishna, Shweta Pandya, Mark S. Hixon, Ruhi Kamran, Shaosong Chu, J. David Lawson, Kengo Okada, Akira Hori, Akio Mizutani, Hidehisa Iwata, Ron de Jong, Barbara Hibner & Patrick Vincent. (2017) MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody. Molecular Cancer Therapeutics 16:7, pages 1269-1278.
Crossref
Crossref
Victoria E. S. Armero, Marie-Pier Tremblay, Andréa Allaire, Simon Boudreault, Camille Martenon-Brodeur, Cyntia Duval, Mathieu Durand, Elvy Lapointe, Philippe Thibault, Maude Tremblay-Létourneau, Jean-Pierre Perreault, Michelle S. Scott & Martin Bisaillon. (2017) Transcriptome-wide analysis of alternative RNA splicing events in Epstein-Barr virus-associated gastric carcinomas. PLOS ONE 12:5, pages e0176880.
Crossref
Crossref
Ravi Salgia. (2017) MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Molecular Cancer Therapeutics 16:4, pages 555-565.
Crossref
Crossref
Johanna C. Bendell, Howard Hochster, Lowell L. Hart, Irfan Firdaus, Joseph R. Mace, Joshua J. McFarlane, Mark Kozloff, Daniel Catenacci, Jessie J. Hsu, Stephen P. Hack, David S. Shames, See-Chun Phan, Hartmut Koeppen & Allen L. Cohn. (2017) A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. The Oncologist 22:3, pages 264-271.
Crossref
Crossref
Eman A. Toraih, Afaf T. Ibrahiem, Manal S. Fawzy, Mohammad H. Hussein, Saeed Awad M. Al-Qahtani & Aly A. M. Shaalan. (2017) MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma. Oxidative Medicine and Cellular Longevity 2017, pages 1-21.
Crossref
Crossref
O. Schadt & A. Blaukat. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
178
203
.
Felice Pasini, Anna Paola Fraccon, Yasmina Modena, Maria Bencivenga, Simone Giacopuzzi, Francesca La Russa, Milena Gusella & Giovanni de Manzoni. (2016) Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?. Gastric Cancer 20:1, pages 31-42.
Crossref
Crossref
José Manuel Ruiz Morales & Daniel Y. C. Heng. 2017. Renal Cell Carcinoma. Renal Cell Carcinoma
237
251
.
Sa Ye, Jiuke Li, Ke Hao, Jianping Yan & Hongbin Zhou. (2016) The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis. Scientific Reports 6:1.
Crossref
Crossref
Darrin Bann, Daniel Deschler & Neerav Goyal. (2016) Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma. Cancers 8:10, pages 87.
Crossref
Crossref
J. Lee, P. Tran & S.J. Klempner. (2016) Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach. Clinical Oncology 28:8, pages e35-e44.
Crossref
Crossref
Simona Cignetto, Chiara Modica, Cristina Chiriaco, Lara Fontani, Paola Milla, Paolo Michieli, Paolo M. Comoglio & Elisa Vigna. (2016) Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody. Molecular Oncology 10:6, pages 938-948.
Crossref
Crossref
Sabina Palma, Ariel O. Zwenger, María V. Croce, Martín C. Abba & Ezequiel Lacunza. (2016) From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy. Clinical Colorectal Cancer 15:2, pages 104-115.
Crossref
Crossref
Michael L. Friedlander, Kenneth Russell, Sherri Millis, Zoran Gatalica, Ryan Bender & Andreas Voss. (2016) Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials. International Journal of Gynecologic Cancer 26:4, pages 648-654.
Crossref
Crossref
Dale R. Miles, David R. Wada, Nelson L. Jumbe, Steven A. Lacy & Linh T. Nguyen. (2016) Population pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in medullary thyroid cancer patients receiving cabozantinib. Anti-Cancer Drugs 27:4, pages 328-341.
Crossref
Crossref
Zhenfu Han, Peter K. W. Harris, Partha Karmakar, Tommy Kim, Ben Y. Owusu, Scott A. Wildman, Lidija Klampfer & James W. Janetka. (2016) α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer. ChemMedChem 11:6, pages 585-599.
Crossref
Crossref
Zhuo ChenShengnan LiuYuan XiaKejian Wu. (2016) MiR-31 Regulates Rho-Associated Kinase-Myosin Light Chain (ROCK-MLC) Pathway and Inhibits Gastric Cancer Invasion: Roles of RhoA. Medical Science Monitor 22, pages 4679-4691.
Crossref
Crossref
Clemens Reuther, Vera Heinzle, Matilde Spampatti, George Vlotides, Enrico de Toni, Gerald Spöttl, Julian Maurer, Svenja Nölting, Burkhard Göke & Christoph J. Auernhammer. (2016) Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for ‘Off-Target' Effects Not Mediated by c-Met Inhibition. Neuroendocrinology 103:3-4, pages 383-401.
Crossref
Crossref
Carlos M. Farinha & Paulo Matos. (2016) Repairing the basic defect in cystic fibrosis - one approach is not enough. FEBS Journal 283:2, pages 246-264.
Crossref
Crossref
Mohamed S. Mady, Mohamed M. Mohyeldin, Hassan Y. Ebrahim, Heba E. Elsayed, Wael E. Houssen, Eman G. Haggag, Randa F. Soliman & Khalid A. El Sayed. (2016) The indole alkaloid meleagrin, from the olive tree endophytic fungus Penicillium chrysogenum, as a novel lead for the control of c-Met-dependent breast cancer proliferation, migration and invasion. Bioorganic & Medicinal Chemistry 24:2, pages 113-122.
Crossref
Crossref
Yun Dai, George Wilson & Liang Qiao. 2017. Encyclopedia of Cancer. Encyclopedia of Cancer
1128
1135
.
W Ruoming, Y Zhen, Z Tengteng & H Jisheng. (2015) RETRACTED ARTICLE: Tumor suppressor microRNA-31 inhibits gastric carcinogenesis by targeting Smad4 and SGPP2. Cancer Gene Therapy 22:12, pages 564-572.
Crossref
Crossref
Joycelyn Lee, Jack Chan & Su Choo. (2015) Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma. Diseases 3:4, pages 306-324.
Crossref
Crossref
Roland Morley, Alison Cardenas, Peter Hawkins, Yasuyo Suzuki, Virginia Paton, See-Chun Phan, Mark Merchant, Jessie Hsu, Wei Yu, Qi Xia, Daniel Koralek, Patricia Luhn & Wassim Aldairy. (2015) Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program. PLOS ONE 10:10, pages e0139679.
Crossref
Crossref
Ruth Vera, Vicente Alonso, Javier Gállego, Encarnación González, Carmen Guillén-Ponce, Carles Pericay, Fernando Rivera, Mª José Safont & Manuel Valladares-Ayerbes. (2015) Current controversies in the management of metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology 76:4, pages 659-677.
Crossref
Crossref
Anna Hultberg, Virginia Morello, Leander Huyghe, Natalie De Jonge, Christophe Blanchetot, Valérie Hanssens, Gitte De Boeck, Karen Silence, Els Festjens, Raimond Heukers, Benjamin Roux, Fabienne Lamballe, Christophe Ginestier, Emmanuelle Charafe-Jauffret, Flavio Maina, Peter Brouckaert, Michael Saunders, Alain Thibault, Torsten Dreier, Hans de Haard & Paolo Michieli. (2015) Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling. Cancer Research 75:16, pages 3373-3383.
Crossref
Crossref
Luigi Marano, Rita Chiari, Alessio Fabozzi, Ferdinando De Vita, Virginia Boccardi, Giandomenico Roviello, Roberto Petrioli, Daniele Marrelli, Franco Roviello & Alberto Patriti. (2015) c-Met targeting in advanced gastric cancer: An open challenge. Cancer Letters 365:1, pages 30-36.
Crossref
Crossref
Anna C. Navis, Sanne A. M. van Lith, Sander M. J. van Duijnhoven, Maaike de Pooter, Bahar Yetkin-Arik, Pieter Wesseling, Wiljan J. A. J. Hendriks, Hanka Venselaar, Marco Timmer, Patricia van Cleef, Paul van Bergen en Henegouwen, Myron G. Best, Thomas D. Wurdinger, Bastiaan B. J. Tops & William P. J. Leenders. (2015) Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein. Acta Neuropathologica 130:1, pages 131-144.
Crossref
Crossref
Garret Skead & Dhirendra Govender. (2015)
Gene of the month:
MET
. Journal of Clinical Pathology 68:6, pages 405-409.
Crossref
Crossref
Cláudia A. LoureiroAna Margarida MatosÂngela Dias-AlvesJoana F. PereiraInna UliyakinaPatrícia BarrosMargarida D. AmaralPaulo Matos. (2015) A molecular switch in the scaffold NHERF1 enables misfolded CFTR to evade the peripheral quality control checkpoint. Science Signaling 8:377.
Crossref
Crossref
Dieter Dorsch, Oliver Schadt, Frank Stieber, Michael Meyring, Ulrich Grädler, Friedhelm Bladt, Manja Friese-Hamim, Christine Knühl, Ulrich Pehl & Andree Blaukat. (2015) Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 25:7, pages 1597-1602.
Crossref
Crossref
Lixia Bai, Rui Mao, Jintao Wang, Ling Ding, Shiwen Jiang, Chenfei Gao, Huijie Kang, Xiao Chen, Xuesong Sun & Juan Xu. (2015) ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins. Medical Oncology 32:3.
Crossref
Crossref
Anna Spina, Valeria De Pasquale, Giuliana Cerulo, Pasquale Cocchiaro, Rossella Della Morte, Luigi Avallone & Luigi Pavone. (2015) HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation. Biomedicines 3:1, pages 71-88.
Crossref
Crossref
Tom Waddell, Sing Yu Moorcraft & David Cunningham. (2014) Potential role of rilotumumab in the treatment of gastric cancer. Immunotherapy 6:12, pages 1243-1253.
Crossref
Crossref
Paul W Sylvester. (2014) Targeting met mediated epithelial‐mesenchymal transition in the treatment of breast cancer. Clinical and Translational Medicine 3:1.
Crossref
Crossref
Joanna Goździk-Spychalska, Katarzyna Szyszka-Barth, Łukasz Spychalski, Katarzyna Ramlau, Jerzy Wójtowicz, Halina Batura-Gabryel & Rodryg Ramlau. (2014) c-MET Inhibitors in the Treatment of Lung Cancer. Current Treatment Options in Oncology 15:4, pages 670-682.
Crossref
Crossref
Y Zhen, L Guanghui & Z Xiefu. (2014) Knockdown of EGFR inhibits growth and invasion of gastric cancer cells. Cancer Gene Therapy 21:11, pages 491-497.
Crossref
Crossref
Yun Dai, George Wilson & Liang Qiao. 2014. Encyclopedia of Cancer. Encyclopedia of Cancer
1
8
.